A Comprehensive Perspective of Probiotics and their Significant Role in Successfully Preventing or Treating Diseases in Both Preventive and Clinical Medicine
Main Article Content
Abstract
The aim and scope of this research/review article is to point out the role of probiotics and their immunomodulins to prevent or treat several incurable, acute and chronic metabolic diseases. The article is written to address physiological role of probiotics to prevent or treat such diseases at a molecular level, to safeguard humanity. It is also the aim of this research/ review article to educate the healthcare professionals on therapeutic aspects of several strains of probiotics, so that they can properly select them to treat their patients with greater efficacy.
This review and research article provides a comprehensive analysis of probiotics, with particular emphasis on their applications and significance in preventive and clinical medicine. The discussion encompasses morphology, cellular functions, distribution and predilection sites of the attachment of probiotics in the human gastrointestinal tract. In addition, definitions, regulatory considerations, and the therapeutic functions of various individual probiotic strains across different genera and species are presented with explicit details. Special attention is given to the biochemical mechanisms underlying the therapeutic effects associated with the prevention or treatment of specific diseases and symptoms, by individual probiotic strains present in multiple mixed strain culture. A major focus is placed on the role of probiotics in the prevention and treatment of hospital-acquired (nosocomial) infections, certain cancers, and several viral infections, with particular emphasis on the recent COVID-19 pandemic caused by the SARS-CoV-2 RNA coronavirus. The article offers a logical explanation of how probiotics may help modulate cytokine storms, a key factor in viral and bacterial infections, several allergies, obesity, and autoimmune disorders. During the course of research aimed at combating COVID-19, several serendipitous findings emerged, revealing potential therapeutic applications of probiotics in managing common conditions such as hypertension and type 2 diabetes. A scientific rationale is presented to explain the pathophysiology of these diseases and how probiotics may offer a novel approach to their treatment. Consequently, a concise pathophysiology of a particular disease has been presented to show exactly and hypothetically at what stage probiotics exert their therapeutic effect, for the sake of better understanding and appreciation by the readers. The article proposes function-specific combinations of probiotic strains that may serve as therapeutic agents for particular diseases or syndromes, offering a practical guide for physicians in clinical settings. The research/review article, presented with simplified and yet detailed schematic and pictorial presentation is an early guide to follow the theme of genesis, physiology, and role of probiotics to be used as preventative or therapeutic aids to prevent or cure several diseases in preventive or clinical medicine set up. For the sake of simplicity more emphasis has been placed on the pictorial presentations than elaborate and complex script for the sake of easy understanding, along with the pertinent references in this article.
Keywords:
Multiple mixed strain probiotic therapy, Probiotics, Bacteriocins, Immunomodulins, Immunomodulation, Cytokine storm, COVID-19, Diabetes, Hypertension, Thrombosis, Anti-ageing, Allergy, Hospital-acquired infections, Nosocomial infections, Autoimmune diseases, Fecal microbiota therapy, SARS CoV-2, C.diff, MRSA, Immune checkpoint cancer therapy, Standard cancer therapy, Adjuvant cancer therapy, US Patent 11,077,052B1, Dysbiosis
Article Details
How to Cite
REDDY, Malireddy S..
A Comprehensive Perspective of Probiotics and their Significant Role in Successfully Preventing or Treating Diseases in Both Preventive and Clinical Medicine.
Medical Research Archives, [S.l.], v. 13, n. 9, sep. 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6915>. Date accessed: 06 dec. 2025.
doi: https://doi.org/10.18103/mra.v13i9.6915.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Lilly DM, Stillwell RH. Probiotics: Growth promoting factors produced by microorganisms. Science. 1965;147: 747-748.
2. Parker RB. Probiotics: The other half of the antibiotic story. J Anim Nutri Health. 1974; 29: 4-8,
3. Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989; 66: 365-378.
4. FAO/WHO. Report on joint FAO/WHO. Expert consultation on evaluation of health and nutritional properties of probiotics in food including powdered milk with live lactic acid bacteria. 2001. (Google scholar). http://www.fao.org/ 3/a0512e/a0512e.pdf
5. Code of Federal Regulations of Food and Drug. Published by office of the Federal Register, National Archives and Records Administration, U.S. Government printing office, Washington, D.C., USA. 2001. http://bookstore.gpo.gov
6. Zhang M, Hang X, Fan X et al. Characterization and selection of Lactobacillus strains for their effect on bile tolerance, taurocholate deconjugation and cholesterol removal. World J Microbiol Bio Technol. 2008; 24(1): 7-14.
7. Ahn YT, Kim GB, Lim KS et al. Deconjugation of bile salts by Lactobacillus acidophilus isolates. Int Dairy J. 2003; 13: 300-311.
8. Anderson JW, Gilliland SE. Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J Am Coll Nutr. 1999; 18:43-50.
9. Tufail M, Husshin S, Malik F et al. Isolation and evaluation of antimicrobial activity of bacteriocin produced by Lactobacillus bulgaricus from yogurt. AFR J Microbiol Res. 2011; 2015: 3842-3847.
10. Vecchi ED, Drago L. Lactobacillus sporogenes or Bacillus coagulans; misidentification or mislabeling. Int J Probio Prebio. 2006;1:3-10. https://www. Seman-ticscholar.org/ paper/Lactobacillus-sporogenes-or-Bacillus-coagulans%3A-or-Vecchi-Drago/-ef3bda2d5cc2275e62aee53d1 c3c8a3f97403b75.
11. Salva S, Villena J, Alverez S. Immunomodulatory activity of Lactobacillus rhamnosus strain isolated from goat milk: Impact on intestinal and respiratory infections. Int J Food Microbiol. 2010; 141:82-89.
12. Liu Y, Yu X, Yu L et al. Lactobacillus plantarum CCFM 8610 alleviates irritable bowel syndrome and prevents gut microbiota dysbiosis: a randomized double blind, placebo-controlled pilot clinical trial. Engineering. 2021; 7: 376-385.
13. . Borchers AT, Selmi C, Meyers FJ et al. Probiotics and Immunity. J Gastroenterol. 2009; 44:26-46.
14. Brashears MM, Gilliland SE, Buck LM. Bile salt deconjugation and cholesterol removal from media by Lactobacillus casei. J Dairy Sci. 1998; 81:2103-2110.
15. Rodriguez C, Medici M, Valdez GF et al. Therapeutic effect of Streptococcus thermophilus CRL-1190-fermented milk on chronic gastritis. World J Gastroenterol. 2010; 16:1622-1630.
16. Sgouras D, Maragkoudakis P, Petraki K et at. In vitro and In vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol . 2004; 70:518-526. doi:10.1128/aem.70.1.518-526.
17. Reddy, MS.. Microbiological Techniques to Study Undue Strain Dominance Among Probiotic Bacteria in Order to Develop Compatible Multiple Mixed Probiotic Cultures to Prevent or Treat Diseases. Medical Research Archives. 2024;12(12);1-21. https://doi.org/10.18103/mra.v13i1.6201.
18. Yamamura S, Morishima H, Kumano-go T et al. The effect of Lactobacillus helveticus fermented milk on sleep and health perception in elderly subjects. Eur J Clin Nutr. 2021; 63:100 105.
19. Hosoya T, Sakai F, Yamashita M et al. Lactobacillus helveticus SBT2171 inhibit lymphocyte proliferation by regulation of the JNK signaling pathway. PLoS One. 9(9) e 108-360. https:// doi. Org/10.1371/ journal.pone. 2014; 0108360.
20. Huang R, Wang K, Hu J. Effect of probiotics on depression: A systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016; 8:483. https.//doi.org/ 10.3390/nu8080483.
21. Liang S, Wang T, Hu X et al. Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress. Neuroscience. 2015; 310:561-577.
22. Saarela M, Lahteenmaki I, Crittenden R et at. Gut bacteria and healthy foods-the European perspective. Int J Food Microbiol. 2002; 78:99-117.
23. Lecomte X, Gagnaire V, Lortal S et al. Streptococcus thermophilus, an emerging and pro liberation of bio peptides from milk for tool for heterologous expression: advantages and future trends. Food Microbiol. 2015; 53: 2-9. 2016 Doi: 10.1016/j.bk.2015. 05.003.
24. Nuryshev M, Stoyanova LLG, Netrusov AI. New probiotic culture of Lactococcus lactis ssp. lactis: Effective opportunities and prospects. J Micro Biochem Technol. 2016; 8: 290-295.
25. Darby TM, Owens JA, Saeedi BJ et al. Lactobacillus lactis subsp. cremoris is an efficacious beneficial bacterium that limits tissue injury in the intestine. Science 2019; 12: 356-367.
26. Perdigon G, Galdeano C, Valdez JC et al. Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr. 2002; 56:521-526.
27. Holo H, Faye T, Brede DA et al. Bacteriocins of propionibacteria. Lait. 2002; 82: 59-68.
28. Jan G, Leverrier P, Proudi I et al. Survival and beneficial effects of Propionibacteria in the human gut. In vivo and In vitro investigations. Lait. 2002; 82:131-144.
29. Jan G, Belzacq S, Haouzi D et al. Propionibacteria induce apoptosis of colorectal carcinoma cells via. short chain fatty acids acting on mitochondria. Cell Deaths Differ. 2002; 9:179-188.
30. Motta AS, Brandelli A. Characterization of an antibacterial peptide produced by Brevibacterium linens. J Appl Microbiol. 2002; 92: 63-70.
31. Reddy MS. Genesis, evaluation, and progression of a breakthrough discovery to efficiently cure cancer through use of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotics as adjuvants along with the traditional cancer therapies, through restoration of healthy and balanced intestinal microbiota and their microbiome. LOJ Phar Cli Res. 2019; 1:107-109.
32. Reddy MS, Reddy DRK. Isolation and determination of the major principle of causative agent behind the 2016 published breakthrough discovery of Dr. M.S. Reddy’s “Multiple Mixed Strain Probiotic Therapy” in successfully treating the lethal hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus Aureus (MRSA). Int J Pharma Sci Nano Tech. 2016; 6: 3556-3566.
33. Reddy MS, Reddy DRK. Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy. J Pharma Nano Technol. 2016; 4: 15-28.
34. Reddy MS, Reddy DRK. Probiotic Therapy. AAPI J. 2009; 28-29.
35. . Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol. 2009; 587:4153-4158.
36. Tisoncik JV, Korth MJ, Simmons CP et al. Into the eye of the cytokine storm. Microbiol. 2012; 76:16-32.
37. Racab D, Eldin HS, Taeimah et al. The COVID-19 Cytokine storm; what we know so far. Front Immunol. 2020; 16(11): 1446. Doi: 10.3389/Fimmu. 2020.01446.
38. Hosseini A, Hashemi V, Shomali N et al. Innate and adaptive responses against Coronoavirus. Biomed Pharmacother. 2020; 132:110859. doi: 10.1016/J. Biohas. 110859.
39. Marfini I, Sedda S, Dinallo V et al. Inflammatory Cytokines: from discoveries to therapies in IBD. Exp Opin Biol Ther. 2019; 19: 1207-1217.
40. Popescu A, Smilbert O, Gibson A et al. The role of IL-6 and other mediators in cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin Immunol. 2020; 146: 518-534.
41. Mangalmurti N, Hunter CA. Cytokine storms: Understanding COVID-19. Immunity 53. 2020; 19-25.
42. Hojyo S, Vchida M, Hirano T. How COVID-19 induce cytokine storm with high mortality. Inflamm Regen 40 2020;37-66.
43. Chen G, Wu D, Guo W et al. Clinical and immunological features of severe and moderate coronavirus disease. J Clin Invest.2019; 130:2620-2629.
44. Chen L, Liu HG, Liu W et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghas Jie HE HE Xl ZA ZHI.2020; 43:203-208.
45. . Iwai Y, Ishida M, Tanaka Y et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci, USA. 2020;99:12293-12297.
46. Iwai Y, Terawaki S, Hanjo T. PD-l blockade inhibits hematogenous spread of poorly immunogenicity tumor cells by enhanced recruitment of effector T-cells. Inter Immunol.2004; 17:133-144.
47. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271: 1734-1736
48. Kocsist, Molanar B, Nemeth D, et al. Probiotics have beneficial metabolic effects in patients with type 2 diabetes mellitus: A meta-analysis of randomized clinical trials. Sci Rep. 2020;10:11787. https://doi.org/10.1038/54195841598-020-68440-1
49. Rittiphairoj T, Pongpirul IK, Janchut K, et al. Probiotics contribute to glycemic control in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Adv Nutr. 2021;12(3):722-734. doi: 10.1093/Advances/Ink Nutrition. nmaa 133
50. Westman EC. Type 2 diabetes mellitus: A pathophysiology perspective. Front Nutr. 2021;8:707371. doi: 10.3389/FNUT.2021.707371.
51. Reed J, Bains, Kanamariapudi V. A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives. Dove Press. 2021;2021:3567-3602.
52. Papatheodorou K, Papanas N, Banach M, Papazoglou D, Edmonds M. Complications of diabetes 2016. J Diabetes Res. 2016;2016:6989453.
53. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50.
54. Chaudhury A, Duvoor C, Reddy Dendi SP, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol. 2017;8:6.
55. Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE. 2010;5:e9085.
56. Million M, Angelakis E, Paul G, et al. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog. 2012;53:100-108.
57. Kannel W, McGee D. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2:120-126.
58. Abarca-Gómez L, Abdeen ZA, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390:2627-2642.
59. Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol. 2009;587:4153-4158.
60. Clarke G, Stilling RM, Kennedy PJ, Quigley EM, Cryan JF, Dinan TG. Minireview: gut microbiota: the neglected endocrine organ. Mol Endocrinol. 2014;28:1221-1238.
61. Chaudhury A, Duvoor C, Reddy Dendi SP, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol. 2017;8:6.
62. Campbell LW. Antidiabetic drugs present and future. Drugs. 2000;60:1017-1028.
63. Rad A, Keshvari S, Yari K, Alizadeh S. The future of diabetes management by healthy probiotic microorganisms. Curr Diabetes Rev. 2017;13:582-589.
64. Ejtahed H, Mohtadi-Nia J, Homayouni-Rad A, et al. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci. 2011;94:3288-3294.
65. Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE. 2010;5:e9085.
66. Zhang Q, Wu Y, Fei Y. Effect of probiotics on glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Medicina. 2016;52:28-34.
67. Kasińska MA, Drzewoski J. Effectiveness of probiotics in type 2 diabetes: a meta-analysis. Pol Arch Med Wewn. 2015;125:803-813.
68. He J, Zhang F, Han Y. Effect of probiotics on lipid profiles and blood pressure in patients with type 2 diabetes: a meta-analysis of RCTs. Medicine. 2017;96:e9166.
69. Yao K, Zeng L, Wang J, et al. Effect of probiotics on glucose and lipid metabolism in type 2 diabetes mellitus: a meta-analysis of 12 randomized controlled trials. Med Sci Monit Int Med J Exp Clin Res. 2017;23:3044.
70. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med. 2009;151:264-269.
71. Bahmani F, Tajadadi-Ebrahimi M, Hekmatdoost A, et al. The consumption of synbiotic bread containing Lactobacillus sporogenes and inulin affects nitric oxide and malondialdehyde in patients with type 2 diabetes mellitus: randomized, double-blind, placebo-controlled trial. J Am Coll Nutr. 2016;35:506-513.
72. Bayat A, Feizollahzadeh S, Ghiasvand R, et al. Effect of Cucurbita ficifolia and probiotic yogurt consumption on blood glucose, lipid profile, and inflammatory marker in type 2 diabetes. Int J Prev Med. 2016;7:30.
73. Hsieh M-C, Tsai W-H, Wu Y-C, et al. The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial. Sci Rep. 2018;8:1-11.
74. Kobyliak N, Abenavoli L, Falalyeyeva T, et al. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial. J Gastrointest Liver Dis. 2018;27:41-49.
75. Król E, Krejpcio Z, Byks H, Bogdański P, Pupek-Musialik D. Effects of chromium brewer's yeast supplementation on body mass, blood carbohydrates, and lipids and minerals in type 2 diabetic patients. Biol Trace Elem Res. 2011;143:726-737.
76. Mafi A, Khademi M, Tavakoli Z, et al. Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial. Food Funct. 2018;9:4763-4770.
77. Mazloom Z, Yousefinejad A, Dabbaghmanesh MH. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. Iran J Med Sci. 2013;38:38.
78. Mohamadshahi M, Aghatabasi F, Mohammadi N. Effects of probiotic yogurt consumption on inflammatory biomarkers in patients with type 2 diabetes. BioImpacts. 2014;4:83.
79. Ostadrahimi A, Taghizadeh S, Kiani MA, et al. Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Iran J Public Health. 2015;44:228.
80. Raygan F, Ostadmohammadi V, Asemi Z. The effects of probiotic and selenium co-supplementation on mental health parameters and metabolic profiles in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38:1594-1598.
81. Raygan F, Ostadmohammadi V, Bahmani F, Asemi Z. The effects of vitamin D and probiotic co-supplementation on mental health parameters and metabolic status in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Prog Neuropsychopharmacol Biol Psych. 2018;84:50-55.
82. Raygan F, Ostadmohammadi V, Bahmani F, Asemi Z. The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease. Diabetol Metab Syndr. 2018;10:51.
83. Tonucci LB, Dos Santos KMO, de Oliveira LL, Ribeiro SMR, Martino HSD. Clinical application of probiotics in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. Clin Nutr. 2017;36:85-92
84. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest. 1984;74:1238-1246. doi:10.1172/JC111533
85. Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinol Metab Clin North Am. 2005;34:49-62. doi:10.1016/j.ecl.2004.12.001
86. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137-149.
87. Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013;4:37.
88. Hegazi R, El-Gamal M, Abdel-Hady N, Hamdy O. Epidemiology of and risk factors for type 2 diabetes in Egypt. Ann Glob Health. 2015;81(6):814-820. doi:10.1016/j.aogh.2015.12.011
89. Chen K, Zheng X, Feng M, Li D, Zhang H. Probiotics: functional food ingredients with the potential to reduce hypertension. Front Cell Infect Microbiol. 2023;13:1220877. doi:10.3389/fcimb.2023.1220877
90. Aoyagi Y, Park S, Matsubara S, Honda Y, Amamoto R, Kushiro A, et al. Habitual intake of fermented milk products containing Lactobacillus casei strain shirota and a reduced risk of hypertension in older people. Benef Microbes. 2017;8:23-29.
91. Gebrayel P, Nicco C, Al Khodor S, Bilinski J, Caselli E, Comelli EM, et al. Microbiota medicine: towards clinical revolution. J Transl Med. 2022;20:111.
92. Guyenet PG, Stornetta RL, Souza G, Abbott SBG, Brooks VL. Neuronal networks in hypertension: recent advances. Hypertension. 2020;76:300-311.
93. Lakshmanan AP, Shatat IF, Zaidan S, Jacob S, Bangarusamy DK, Al-Abduljabbar S, et al. Bifidobacterium reduction is associated with high blood pressure in children with type 1 diabetes mellitus. BioMed Pharmacother. 2021;140:111736.
94. Li J, Yang X, Zhou X, Cai J. The role and mechanism of intestinal flora in blood pressure regulation and hypertension development. Antioxid Redox Signal. 2021;34:811-830.
95. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5:14.
96. O'Donnell JA, Zheng T, Meric G, Marques FZ. The gut microbiome and hypertension. Nat Rev Nephrol. 2023;19(3):153-167.
97. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65:1331-1340.
98. Zhu B, Wang X, Li L. Human gut microbiome: the second genome of human body. Protein Cell. 2010;1(7):718-725.
99. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837-848.
100. Wolf KJ, Lorenz RG. Gut microbiota and obesity. Curr Obes Rep. 2012;1(1):1-8.
101. Fletcher GF, Grundy SM, Hayman LL. Obesity: impact on cardiovascular disease. Circulation. 1998;98(14):1472-1476.
102. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011;121(6):2126-2132.
103. Ley R, Turnbaugh P, Klein S, Gordon J. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-1023.
104. Catalan V, Gomez-Ambrosi J, Ramirez B, Rotellar F, Pastor C, Silva C. Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg. 2008;18(1):87-98.
105. Sato J, Kanazawa A, Azuma K, et al. Probiotic reduces bacterial translocation in type 2 diabetes mellitus: a randomised controlled study. Sci Rep. 2017;7:1-10.
106. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-1772.
107. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718-15723.
108. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070-11075.
109. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. From the cover: mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104(3):979-984.
110. Peters SA, Singhateh Y, Mackay D, Huxley RR, Woodward M. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: a systematic review and meta-analysis. Atherosclerosis. 2016;248:123-131.
111. Lye H-S, Kuan C-Y, Ewe J-A, Fung W-Y, Liong M-T. The improvement of hypertension by probiotics: effects on cholesterol, diabetes, renin, and phytoestrogens. Int J Mol Sci. 2009;10:3755-3775.
112. Gu S, Yang D, Liu C, Xue W. The role of probiotics in prevention and treatment of food allergy. Food Sci Hum Wellness. 2023;12(3):681-690.
113. Food Allergy Research & Education. Gut Bacteria That Protect Against Food Allergies Identified. Published August 25, 2014. Accessed August 15, 2025. https://www.foodallergy.org/resources/gut-bacteria-protect-against-food-allergies-identified
114. Urisu A, Ebisawa M, Ito K, et al. Japanese guideline for food allergy 2014. Allergol Int. 2014;63:399-419.
115. Prescott S, Allen KJ. Food allergy: riding the second wave of the allergy epidemic. Pediatr Allergy Immunol. 2011;22:155-160.
116. Huang CH, Shen CC, Liang YC, et al. The probiotic activity of Lactobacillus murinus against food allergies. J Funct Food. 2016;25:231-241.
117. Turner PJ, Campbell DE, Boyle RJ, et al. Primary prevention of food allergy: translating evidence from clinical trials to population-based recommendations. J Allergy Clin Immunol Pract. 2018;6:367-375.
118. Lim SM, Kim DH. Bifidobacterium adolescentis IM38 ameliorates high-fat diet-induced colitis in mice by inhibiting NF-κB activation and lipopolysaccharide production by gut microbiota. Nutr Res. 2017;41:86-96.
119. Gao J, Xu K, Liu HN, et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol. 2018;8:13.
120. Ma JY, Zhang J, Li QH, et al. Oral administration of a mixture of probiotics protects against food allergy via induction of CD103+ dendritic cells and modulates the intestinal microbiota. J Funct Food. 2019;55:65-75.
121. Nwaru BI, Hickstein L, Panesar SS, et al. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy. 2014;69:992-1007.
122. Greenhawt M, Weiss C, Conte ML, et al. Racial and ethnic disparity in food allergy in the United States: a systematic review. J Allergy Clin Immunol Pract. 2013;1:378-386.
123. Yahfoufi N, Mallet JF, Graham E, et al. Role of probiotics and prebiotics in immunomodulation. Curr Opin Food Sci. 2018;20:82-91.
124. Sun CM, Hall JA, Blank RB, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 Treg cells via retinoic acid. J Exp Med. 2007;204:1775-1785.
125. Morita H, Nomura I, Orihara K, et al. Antigen-specific T-cell responses in patients with non-IgE-mediated gastrointestinal food allergy are predominantly skewed to Th2. J Allergy Clin Immunol. 2013;131:590-592.
126. Konstantinou GN, Bencharitiwong R, Grishin A, et al. The role of casein-specific IgA and TGF-β in children with food protein-induced enterocolitis syndrome to milk. Pediatr Allergy Immunol. 2014;25:651-656.
127. Canani RB, Paparo L, Nocerino R, et al. Gut microbiome as target for innovative strategies against food allergy. Front Immunol. 2019;10:191.
128. Bunyavanich S, Berin MC. Food allergy and the microbiome: current understandings and future directions. J Allergy Clin Immunol. 2019;144:1468-1477.
129. Sharma G, Im SH. Probiotics as a potential immunomodulating pharmabiotics in allergic diseases: current status and future prospects. Allergy Asthma Immunol Res. 2018;10:575-590.
130. Abdel-Gadir A, Stephen-Victor E, Gerber GK, et al. Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergy. Nat Med. 2019;25:1164-1174.
131. Tan J, Mckenzie C, Vuillermin PJ, et al. Dietary fiber and bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular pathways. Cell Rep. 2016;15:2809-2824.
132. Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500:232-236.
133. Boyle RJ, Ismail IH, Kivivuori S, et al. Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial. Allergy. 2011;66:509-516.
134. Shu SA, Yuen AWT, Woo E, et al. Microbiota and food allergy. Clin Rev Allergy Immunol. 2019;57:83-97.
135. Sestito S, D'auria E, Baldassarre ME, et al. The role of prebiotics and probiotics in prevention of allergic diseases in infants. Front Pediatr. 2020;8:583946.
136. Yousefi B, Eslami M, Ghasemian A, et al. Probiotics importance and their immunomodulatory properties. J Cell Physiol. 2019;234:8008-8018.
137. Jones SE, Paynich ML, Kearns DB, et al. Protection from intestinal inflammation by bacterial exopolysaccharides. J Immunol. 2014;192:4813-4820.
138. Guo SS, Gillingham T, Guo YM, et al. Secretions of Bifidobacterium infantis and Lactobacillus acidophilus protect intestinal epithelial barrier function. J Pediatr Gastroenterol Nutr. 2017;64:404-412.
139. Cox MJ, Huang YJ, Fujimura KE, et al. Lactobacillus casei abundance is associated with profound shifts in the infant gut microbiome. PLoS ONE. 2010;5:e8745.
140. Canani RB, Sangwan N, Stefka AT, et al. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants. ISME J. 2016;10:742-750.
141. Fu L, Fu S, Wang C. Yogurt-sourced probiotic bacteria alleviate shrimp tropomyosin-induced allergic mucosal disorders, potentially through microbiota and metabolism modifications. Allergol Int. 2019;68:506-514.
142. Kepert I, Fonseca J, Muller C, et al. D-tryptophan from probiotic bacteria influences the gut microbiome and allergic airway disease. J Allergy Clin Immunol. 2017;139:1525-1535.
143. Kim S, Kim JH, Park BO, et al. Perspectives on the therapeutic potential of short-chain fatty acid receptors. Bmb Rep. 2014;47:173-178.
144. Overby HB, Ferguson JF. Gut microbiota-derived short-chain fatty acids facilitate microbiota: host cross talk and modulate obesity and hypertension. Curr Hypertens Rep. 2021;23:8.
145. Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. Proc Nutr Soc. 2003;62:67-72.
146. Goverse G, Molenaar R, Macia L, et al. Diet-derived short chain fatty acids stimulate intestinal epithelial cells to induce mucosal tolerogenic dendritic cells. J Immunol. 2017;198:2172-2181.
147. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451-455.
148. Kim JH, Jeun EJ, Hong CP, et al. Extracellular vesicle-derived protein from Bifidobacterium longum alleviates food allergy through mast cell suppression. J Allergy Clin Immunol. 2016;137:507-516.
149. Lee SY, Lee SH, Jhun J, et al. A combination with probiotic complex, zinc, and coenzyme Q10 attenuates autoimmune arthritis by regulation of Th17/Treg balance. J Med Food. 2018;21:39-46.
150. Huang CH, Lin YC, Jan TR. Lactobacillus reuteri induces intestinal immune tolerance against food allergy in mice. J Funct Food. 2017;31:44-51.
151. Hyung KE, Moon BS, Kim B, et al. Lactobacillus plantarum isolated from kimchi suppress food allergy by modulating cytokine production and mast cells activation. J Funct Food. 2017;29:60-68.
152. Choudhary P, Kathuria D, Suri S, et al. Fecal probiotics-its functions and influence on the ageing process: a comprehensive review. Biocatal Agric Biotechnol. 2023;52:102389.
153. Reddy MS, Reddy DRK. Anti-aging: review and experimental clinical study of bio available calcium. Int J Pharm Sci Nanotech. 2011;4(1):1436-1444.
154. Amara AA, Shibl A. Role of probiotics in health improvement, infection control and disease treatment and management. Saudi Pharm J. 2015;23(2):107-114.
155. Bektas A, Schurman SH, Sen R, Ferrucci L. Aging, inflammation and the environment. Exp Gerontol. 2018;105:10-18.
156. Butel MJ. Probiotics, gut microbiota and health. Med Mal Infect. 2014;44(1):1-8.
157. Ferrucci L, Corsi A, Lauretani F, et al. The origins of age-related proinflammatory state. Blood. 2005;105(6):2294-2299.
158. Finamore A, Roselli M, Imbinto A, Sepe Almada P, Mengheri E. Supplementation with Bifidobacterium longum Bar33 and Lactobacillus helveticus Bar13 mixture improves immunity in elderly humans (over 75 years) and aged mice. Nutrition. 2019;63-64:184-192.
159. Foster JA, Rinaman L, Cryan JF. Stress & the gut-brain axis: regulation by the microbiome. Neurobiol Stress. 2017;7:124-136.
160. Hachem JP, Crumrine D, Fluhr J, Brown BE, Feingold KR, Elias PM. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. J Invest Dermatol. 2003;121(2):345-353.
161. Reddy MS. Selected Multiphase Treatment for Coronavirus Respiratory Infections. US Patent 11,077,052 B1. August 3, 2021.
162. Reddy, MS. Mechanism of Thrombosis During COVID-19 Infection Due to SARS-CoV-2 Virus and its Variants, and a Clinically Proven Strategy to Combat with Probiotics and their Immunomodulins. Medical Research Archives. 2022;10(9);1-21. https://doi.org/10.18103/mra.v10i9.3075.
163. Reddy MS. Scientific and medical research on Dr. M.S. Reddy’s multiple mixed strain probiotic therapy and its influence on assisting to cure or prevent the nosocomial infections, synergistically enhancing the conventional cancer therapies, as an adjuvant, and its possible potential to prevent or cure COVID-19 novel Coronavirus infection by balancing the intestinal microbiota and microbiome through modulation of the human immune system. Int J Pharm Sci Nanotech. 2020;13(3):4876-4906.
164. Reddy MS. Prevention of Viral Transmission by Naked Genetic Material. US Patent 11,643,641 B2. May 9, 2023.
165. Reddy MS, Reddy DRK, Prasad NAV. Herbal and Pharmaceutical Drugs Enhanced with Probiotics. US Patent 6,080,401. June 27, 2000.
166. Reddy MS, Reddy DRK. Development of multiple mixed strain probiotics for “probiotic therapy” under clinical conditions, to prevent or cure the deadly hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus aureus (MRSA). Int J Pharm Sci Nanotech. 2016;9(3):3256-3281.
167. Reddy MS. Probiotics: genesis, current definition, and proven therapeutic properties. JAAPI. 2021;1(2):18-26.
168. Reddy MS. Proven novel method to curtail COVID-19 pandemic, long COVID, any further viral pandemics, including influenza due to RNA/DNA viruses, through inactivation of their naked RNA/DNA, and hospital acquired (nosocomial) infections. Arch Neurol & Neurosci. 2023;16(1):1-20.
169. Reddy MS. Dr. M.S. Reddy’s multiple mixed strain probiotics adjuvant cancer therapy, to complement immune check point therapy and other traditional cancer therapies, with least autoimmune side effects through eco-balance of human microbiome. Int J Pharm Sci Nanotech. 2018;11(6):4295-4317.
170. Reddy MS. Immunomodulatory effect of “Dr. M.S. Reddy’s multiple mixed strain probiotic therapy “, to cure or prevent hospital acquired (nosocomial) infections due to Clostridium difficile (C. diff), other pathogenic bacteria and autoimmune diseases. Int J Pharm Sci Nanotech. 2018;11(1):3937-3949.
171. Reddy MS, Reddy DRK. Isolation and the determination of the major principle or causative agent behind the 2016 published breakthrough discovery of Dr. M. S. Reddy’s “multiple mixed strain probiotic therapy “, in successfully treating the lethal hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus aureus (MRSA). Int J Pharm Sci Nanotech. 2016;9(6):3556-3566.
172. Reddy MS, Reddy DRK. Therapeutic probiotics for cancer reduction. AAPI Journal. 2015;May/June:55-56.
173. Reddy MS, Reddy DRK. Probiotics, biotechnology, and Ayurvedic herbs - complementary and alternative medicine. AAPI Journal. 2004;May/June:32-33.
174. Reddy MS. Mechanism of cytokine storm in COVID-19: how can probiotics combat it? JAAPI. 2021;1(3):27-35.
175. Reddy MS. The Role of Prokaryotic (Probiotic) Produced Megamicro RNAs (memiRNAs) to Prevent or Cure Viral and Nosocomial Infections, Certain Cancers, in Conjunction with Probiotic Induced Eukaryotic Micro RNAs (miRNAs). Med Res Arch. 2024;12(12):1-21. doi:10.18103/mra.v12i12.6179
2. Parker RB. Probiotics: The other half of the antibiotic story. J Anim Nutri Health. 1974; 29: 4-8,
3. Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989; 66: 365-378.
4. FAO/WHO. Report on joint FAO/WHO. Expert consultation on evaluation of health and nutritional properties of probiotics in food including powdered milk with live lactic acid bacteria. 2001. (Google scholar). http://www.fao.org/ 3/a0512e/a0512e.pdf
5. Code of Federal Regulations of Food and Drug. Published by office of the Federal Register, National Archives and Records Administration, U.S. Government printing office, Washington, D.C., USA. 2001. http://bookstore.gpo.gov
6. Zhang M, Hang X, Fan X et al. Characterization and selection of Lactobacillus strains for their effect on bile tolerance, taurocholate deconjugation and cholesterol removal. World J Microbiol Bio Technol. 2008; 24(1): 7-14.
7. Ahn YT, Kim GB, Lim KS et al. Deconjugation of bile salts by Lactobacillus acidophilus isolates. Int Dairy J. 2003; 13: 300-311.
8. Anderson JW, Gilliland SE. Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J Am Coll Nutr. 1999; 18:43-50.
9. Tufail M, Husshin S, Malik F et al. Isolation and evaluation of antimicrobial activity of bacteriocin produced by Lactobacillus bulgaricus from yogurt. AFR J Microbiol Res. 2011; 2015: 3842-3847.
10. Vecchi ED, Drago L. Lactobacillus sporogenes or Bacillus coagulans; misidentification or mislabeling. Int J Probio Prebio. 2006;1:3-10. https://www. Seman-ticscholar.org/ paper/Lactobacillus-sporogenes-or-Bacillus-coagulans%3A-or-Vecchi-Drago/-ef3bda2d5cc2275e62aee53d1 c3c8a3f97403b75.
11. Salva S, Villena J, Alverez S. Immunomodulatory activity of Lactobacillus rhamnosus strain isolated from goat milk: Impact on intestinal and respiratory infections. Int J Food Microbiol. 2010; 141:82-89.
12. Liu Y, Yu X, Yu L et al. Lactobacillus plantarum CCFM 8610 alleviates irritable bowel syndrome and prevents gut microbiota dysbiosis: a randomized double blind, placebo-controlled pilot clinical trial. Engineering. 2021; 7: 376-385.
13. . Borchers AT, Selmi C, Meyers FJ et al. Probiotics and Immunity. J Gastroenterol. 2009; 44:26-46.
14. Brashears MM, Gilliland SE, Buck LM. Bile salt deconjugation and cholesterol removal from media by Lactobacillus casei. J Dairy Sci. 1998; 81:2103-2110.
15. Rodriguez C, Medici M, Valdez GF et al. Therapeutic effect of Streptococcus thermophilus CRL-1190-fermented milk on chronic gastritis. World J Gastroenterol. 2010; 16:1622-1630.
16. Sgouras D, Maragkoudakis P, Petraki K et at. In vitro and In vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol . 2004; 70:518-526. doi:10.1128/aem.70.1.518-526.
17. Reddy, MS.. Microbiological Techniques to Study Undue Strain Dominance Among Probiotic Bacteria in Order to Develop Compatible Multiple Mixed Probiotic Cultures to Prevent or Treat Diseases. Medical Research Archives. 2024;12(12);1-21. https://doi.org/10.18103/mra.v13i1.6201.
18. Yamamura S, Morishima H, Kumano-go T et al. The effect of Lactobacillus helveticus fermented milk on sleep and health perception in elderly subjects. Eur J Clin Nutr. 2021; 63:100 105.
19. Hosoya T, Sakai F, Yamashita M et al. Lactobacillus helveticus SBT2171 inhibit lymphocyte proliferation by regulation of the JNK signaling pathway. PLoS One. 9(9) e 108-360. https:// doi. Org/10.1371/ journal.pone. 2014; 0108360.
20. Huang R, Wang K, Hu J. Effect of probiotics on depression: A systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016; 8:483. https.//doi.org/ 10.3390/nu8080483.
21. Liang S, Wang T, Hu X et al. Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress. Neuroscience. 2015; 310:561-577.
22. Saarela M, Lahteenmaki I, Crittenden R et at. Gut bacteria and healthy foods-the European perspective. Int J Food Microbiol. 2002; 78:99-117.
23. Lecomte X, Gagnaire V, Lortal S et al. Streptococcus thermophilus, an emerging and pro liberation of bio peptides from milk for tool for heterologous expression: advantages and future trends. Food Microbiol. 2015; 53: 2-9. 2016 Doi: 10.1016/j.bk.2015. 05.003.
24. Nuryshev M, Stoyanova LLG, Netrusov AI. New probiotic culture of Lactococcus lactis ssp. lactis: Effective opportunities and prospects. J Micro Biochem Technol. 2016; 8: 290-295.
25. Darby TM, Owens JA, Saeedi BJ et al. Lactobacillus lactis subsp. cremoris is an efficacious beneficial bacterium that limits tissue injury in the intestine. Science 2019; 12: 356-367.
26. Perdigon G, Galdeano C, Valdez JC et al. Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr. 2002; 56:521-526.
27. Holo H, Faye T, Brede DA et al. Bacteriocins of propionibacteria. Lait. 2002; 82: 59-68.
28. Jan G, Leverrier P, Proudi I et al. Survival and beneficial effects of Propionibacteria in the human gut. In vivo and In vitro investigations. Lait. 2002; 82:131-144.
29. Jan G, Belzacq S, Haouzi D et al. Propionibacteria induce apoptosis of colorectal carcinoma cells via. short chain fatty acids acting on mitochondria. Cell Deaths Differ. 2002; 9:179-188.
30. Motta AS, Brandelli A. Characterization of an antibacterial peptide produced by Brevibacterium linens. J Appl Microbiol. 2002; 92: 63-70.
31. Reddy MS. Genesis, evaluation, and progression of a breakthrough discovery to efficiently cure cancer through use of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotics as adjuvants along with the traditional cancer therapies, through restoration of healthy and balanced intestinal microbiota and their microbiome. LOJ Phar Cli Res. 2019; 1:107-109.
32. Reddy MS, Reddy DRK. Isolation and determination of the major principle of causative agent behind the 2016 published breakthrough discovery of Dr. M.S. Reddy’s “Multiple Mixed Strain Probiotic Therapy” in successfully treating the lethal hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus Aureus (MRSA). Int J Pharma Sci Nano Tech. 2016; 6: 3556-3566.
33. Reddy MS, Reddy DRK. Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy. J Pharma Nano Technol. 2016; 4: 15-28.
34. Reddy MS, Reddy DRK. Probiotic Therapy. AAPI J. 2009; 28-29.
35. . Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol. 2009; 587:4153-4158.
36. Tisoncik JV, Korth MJ, Simmons CP et al. Into the eye of the cytokine storm. Microbiol. 2012; 76:16-32.
37. Racab D, Eldin HS, Taeimah et al. The COVID-19 Cytokine storm; what we know so far. Front Immunol. 2020; 16(11): 1446. Doi: 10.3389/Fimmu. 2020.01446.
38. Hosseini A, Hashemi V, Shomali N et al. Innate and adaptive responses against Coronoavirus. Biomed Pharmacother. 2020; 132:110859. doi: 10.1016/J. Biohas. 110859.
39. Marfini I, Sedda S, Dinallo V et al. Inflammatory Cytokines: from discoveries to therapies in IBD. Exp Opin Biol Ther. 2019; 19: 1207-1217.
40. Popescu A, Smilbert O, Gibson A et al. The role of IL-6 and other mediators in cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin Immunol. 2020; 146: 518-534.
41. Mangalmurti N, Hunter CA. Cytokine storms: Understanding COVID-19. Immunity 53. 2020; 19-25.
42. Hojyo S, Vchida M, Hirano T. How COVID-19 induce cytokine storm with high mortality. Inflamm Regen 40 2020;37-66.
43. Chen G, Wu D, Guo W et al. Clinical and immunological features of severe and moderate coronavirus disease. J Clin Invest.2019; 130:2620-2629.
44. Chen L, Liu HG, Liu W et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghas Jie HE HE Xl ZA ZHI.2020; 43:203-208.
45. . Iwai Y, Ishida M, Tanaka Y et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci, USA. 2020;99:12293-12297.
46. Iwai Y, Terawaki S, Hanjo T. PD-l blockade inhibits hematogenous spread of poorly immunogenicity tumor cells by enhanced recruitment of effector T-cells. Inter Immunol.2004; 17:133-144.
47. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271: 1734-1736
48. Kocsist, Molanar B, Nemeth D, et al. Probiotics have beneficial metabolic effects in patients with type 2 diabetes mellitus: A meta-analysis of randomized clinical trials. Sci Rep. 2020;10:11787. https://doi.org/10.1038/54195841598-020-68440-1
49. Rittiphairoj T, Pongpirul IK, Janchut K, et al. Probiotics contribute to glycemic control in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Adv Nutr. 2021;12(3):722-734. doi: 10.1093/Advances/Ink Nutrition. nmaa 133
50. Westman EC. Type 2 diabetes mellitus: A pathophysiology perspective. Front Nutr. 2021;8:707371. doi: 10.3389/FNUT.2021.707371.
51. Reed J, Bains, Kanamariapudi V. A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives. Dove Press. 2021;2021:3567-3602.
52. Papatheodorou K, Papanas N, Banach M, Papazoglou D, Edmonds M. Complications of diabetes 2016. J Diabetes Res. 2016;2016:6989453.
53. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50.
54. Chaudhury A, Duvoor C, Reddy Dendi SP, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol. 2017;8:6.
55. Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE. 2010;5:e9085.
56. Million M, Angelakis E, Paul G, et al. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog. 2012;53:100-108.
57. Kannel W, McGee D. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2:120-126.
58. Abarca-Gómez L, Abdeen ZA, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390:2627-2642.
59. Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol. 2009;587:4153-4158.
60. Clarke G, Stilling RM, Kennedy PJ, Quigley EM, Cryan JF, Dinan TG. Minireview: gut microbiota: the neglected endocrine organ. Mol Endocrinol. 2014;28:1221-1238.
61. Chaudhury A, Duvoor C, Reddy Dendi SP, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol. 2017;8:6.
62. Campbell LW. Antidiabetic drugs present and future. Drugs. 2000;60:1017-1028.
63. Rad A, Keshvari S, Yari K, Alizadeh S. The future of diabetes management by healthy probiotic microorganisms. Curr Diabetes Rev. 2017;13:582-589.
64. Ejtahed H, Mohtadi-Nia J, Homayouni-Rad A, et al. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci. 2011;94:3288-3294.
65. Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE. 2010;5:e9085.
66. Zhang Q, Wu Y, Fei Y. Effect of probiotics on glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Medicina. 2016;52:28-34.
67. Kasińska MA, Drzewoski J. Effectiveness of probiotics in type 2 diabetes: a meta-analysis. Pol Arch Med Wewn. 2015;125:803-813.
68. He J, Zhang F, Han Y. Effect of probiotics on lipid profiles and blood pressure in patients with type 2 diabetes: a meta-analysis of RCTs. Medicine. 2017;96:e9166.
69. Yao K, Zeng L, Wang J, et al. Effect of probiotics on glucose and lipid metabolism in type 2 diabetes mellitus: a meta-analysis of 12 randomized controlled trials. Med Sci Monit Int Med J Exp Clin Res. 2017;23:3044.
70. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med. 2009;151:264-269.
71. Bahmani F, Tajadadi-Ebrahimi M, Hekmatdoost A, et al. The consumption of synbiotic bread containing Lactobacillus sporogenes and inulin affects nitric oxide and malondialdehyde in patients with type 2 diabetes mellitus: randomized, double-blind, placebo-controlled trial. J Am Coll Nutr. 2016;35:506-513.
72. Bayat A, Feizollahzadeh S, Ghiasvand R, et al. Effect of Cucurbita ficifolia and probiotic yogurt consumption on blood glucose, lipid profile, and inflammatory marker in type 2 diabetes. Int J Prev Med. 2016;7:30.
73. Hsieh M-C, Tsai W-H, Wu Y-C, et al. The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial. Sci Rep. 2018;8:1-11.
74. Kobyliak N, Abenavoli L, Falalyeyeva T, et al. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial. J Gastrointest Liver Dis. 2018;27:41-49.
75. Król E, Krejpcio Z, Byks H, Bogdański P, Pupek-Musialik D. Effects of chromium brewer's yeast supplementation on body mass, blood carbohydrates, and lipids and minerals in type 2 diabetic patients. Biol Trace Elem Res. 2011;143:726-737.
76. Mafi A, Khademi M, Tavakoli Z, et al. Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial. Food Funct. 2018;9:4763-4770.
77. Mazloom Z, Yousefinejad A, Dabbaghmanesh MH. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. Iran J Med Sci. 2013;38:38.
78. Mohamadshahi M, Aghatabasi F, Mohammadi N. Effects of probiotic yogurt consumption on inflammatory biomarkers in patients with type 2 diabetes. BioImpacts. 2014;4:83.
79. Ostadrahimi A, Taghizadeh S, Kiani MA, et al. Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Iran J Public Health. 2015;44:228.
80. Raygan F, Ostadmohammadi V, Asemi Z. The effects of probiotic and selenium co-supplementation on mental health parameters and metabolic profiles in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38:1594-1598.
81. Raygan F, Ostadmohammadi V, Bahmani F, Asemi Z. The effects of vitamin D and probiotic co-supplementation on mental health parameters and metabolic status in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Prog Neuropsychopharmacol Biol Psych. 2018;84:50-55.
82. Raygan F, Ostadmohammadi V, Bahmani F, Asemi Z. The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease. Diabetol Metab Syndr. 2018;10:51.
83. Tonucci LB, Dos Santos KMO, de Oliveira LL, Ribeiro SMR, Martino HSD. Clinical application of probiotics in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. Clin Nutr. 2017;36:85-92
84. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest. 1984;74:1238-1246. doi:10.1172/JC111533
85. Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinol Metab Clin North Am. 2005;34:49-62. doi:10.1016/j.ecl.2004.12.001
86. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137-149.
87. Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013;4:37.
88. Hegazi R, El-Gamal M, Abdel-Hady N, Hamdy O. Epidemiology of and risk factors for type 2 diabetes in Egypt. Ann Glob Health. 2015;81(6):814-820. doi:10.1016/j.aogh.2015.12.011
89. Chen K, Zheng X, Feng M, Li D, Zhang H. Probiotics: functional food ingredients with the potential to reduce hypertension. Front Cell Infect Microbiol. 2023;13:1220877. doi:10.3389/fcimb.2023.1220877
90. Aoyagi Y, Park S, Matsubara S, Honda Y, Amamoto R, Kushiro A, et al. Habitual intake of fermented milk products containing Lactobacillus casei strain shirota and a reduced risk of hypertension in older people. Benef Microbes. 2017;8:23-29.
91. Gebrayel P, Nicco C, Al Khodor S, Bilinski J, Caselli E, Comelli EM, et al. Microbiota medicine: towards clinical revolution. J Transl Med. 2022;20:111.
92. Guyenet PG, Stornetta RL, Souza G, Abbott SBG, Brooks VL. Neuronal networks in hypertension: recent advances. Hypertension. 2020;76:300-311.
93. Lakshmanan AP, Shatat IF, Zaidan S, Jacob S, Bangarusamy DK, Al-Abduljabbar S, et al. Bifidobacterium reduction is associated with high blood pressure in children with type 1 diabetes mellitus. BioMed Pharmacother. 2021;140:111736.
94. Li J, Yang X, Zhou X, Cai J. The role and mechanism of intestinal flora in blood pressure regulation and hypertension development. Antioxid Redox Signal. 2021;34:811-830.
95. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5:14.
96. O'Donnell JA, Zheng T, Meric G, Marques FZ. The gut microbiome and hypertension. Nat Rev Nephrol. 2023;19(3):153-167.
97. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65:1331-1340.
98. Zhu B, Wang X, Li L. Human gut microbiome: the second genome of human body. Protein Cell. 2010;1(7):718-725.
99. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837-848.
100. Wolf KJ, Lorenz RG. Gut microbiota and obesity. Curr Obes Rep. 2012;1(1):1-8.
101. Fletcher GF, Grundy SM, Hayman LL. Obesity: impact on cardiovascular disease. Circulation. 1998;98(14):1472-1476.
102. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011;121(6):2126-2132.
103. Ley R, Turnbaugh P, Klein S, Gordon J. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-1023.
104. Catalan V, Gomez-Ambrosi J, Ramirez B, Rotellar F, Pastor C, Silva C. Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg. 2008;18(1):87-98.
105. Sato J, Kanazawa A, Azuma K, et al. Probiotic reduces bacterial translocation in type 2 diabetes mellitus: a randomised controlled study. Sci Rep. 2017;7:1-10.
106. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-1772.
107. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718-15723.
108. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070-11075.
109. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. From the cover: mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104(3):979-984.
110. Peters SA, Singhateh Y, Mackay D, Huxley RR, Woodward M. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: a systematic review and meta-analysis. Atherosclerosis. 2016;248:123-131.
111. Lye H-S, Kuan C-Y, Ewe J-A, Fung W-Y, Liong M-T. The improvement of hypertension by probiotics: effects on cholesterol, diabetes, renin, and phytoestrogens. Int J Mol Sci. 2009;10:3755-3775.
112. Gu S, Yang D, Liu C, Xue W. The role of probiotics in prevention and treatment of food allergy. Food Sci Hum Wellness. 2023;12(3):681-690.
113. Food Allergy Research & Education. Gut Bacteria That Protect Against Food Allergies Identified. Published August 25, 2014. Accessed August 15, 2025. https://www.foodallergy.org/resources/gut-bacteria-protect-against-food-allergies-identified
114. Urisu A, Ebisawa M, Ito K, et al. Japanese guideline for food allergy 2014. Allergol Int. 2014;63:399-419.
115. Prescott S, Allen KJ. Food allergy: riding the second wave of the allergy epidemic. Pediatr Allergy Immunol. 2011;22:155-160.
116. Huang CH, Shen CC, Liang YC, et al. The probiotic activity of Lactobacillus murinus against food allergies. J Funct Food. 2016;25:231-241.
117. Turner PJ, Campbell DE, Boyle RJ, et al. Primary prevention of food allergy: translating evidence from clinical trials to population-based recommendations. J Allergy Clin Immunol Pract. 2018;6:367-375.
118. Lim SM, Kim DH. Bifidobacterium adolescentis IM38 ameliorates high-fat diet-induced colitis in mice by inhibiting NF-κB activation and lipopolysaccharide production by gut microbiota. Nutr Res. 2017;41:86-96.
119. Gao J, Xu K, Liu HN, et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol. 2018;8:13.
120. Ma JY, Zhang J, Li QH, et al. Oral administration of a mixture of probiotics protects against food allergy via induction of CD103+ dendritic cells and modulates the intestinal microbiota. J Funct Food. 2019;55:65-75.
121. Nwaru BI, Hickstein L, Panesar SS, et al. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy. 2014;69:992-1007.
122. Greenhawt M, Weiss C, Conte ML, et al. Racial and ethnic disparity in food allergy in the United States: a systematic review. J Allergy Clin Immunol Pract. 2013;1:378-386.
123. Yahfoufi N, Mallet JF, Graham E, et al. Role of probiotics and prebiotics in immunomodulation. Curr Opin Food Sci. 2018;20:82-91.
124. Sun CM, Hall JA, Blank RB, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 Treg cells via retinoic acid. J Exp Med. 2007;204:1775-1785.
125. Morita H, Nomura I, Orihara K, et al. Antigen-specific T-cell responses in patients with non-IgE-mediated gastrointestinal food allergy are predominantly skewed to Th2. J Allergy Clin Immunol. 2013;131:590-592.
126. Konstantinou GN, Bencharitiwong R, Grishin A, et al. The role of casein-specific IgA and TGF-β in children with food protein-induced enterocolitis syndrome to milk. Pediatr Allergy Immunol. 2014;25:651-656.
127. Canani RB, Paparo L, Nocerino R, et al. Gut microbiome as target for innovative strategies against food allergy. Front Immunol. 2019;10:191.
128. Bunyavanich S, Berin MC. Food allergy and the microbiome: current understandings and future directions. J Allergy Clin Immunol. 2019;144:1468-1477.
129. Sharma G, Im SH. Probiotics as a potential immunomodulating pharmabiotics in allergic diseases: current status and future prospects. Allergy Asthma Immunol Res. 2018;10:575-590.
130. Abdel-Gadir A, Stephen-Victor E, Gerber GK, et al. Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergy. Nat Med. 2019;25:1164-1174.
131. Tan J, Mckenzie C, Vuillermin PJ, et al. Dietary fiber and bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular pathways. Cell Rep. 2016;15:2809-2824.
132. Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500:232-236.
133. Boyle RJ, Ismail IH, Kivivuori S, et al. Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial. Allergy. 2011;66:509-516.
134. Shu SA, Yuen AWT, Woo E, et al. Microbiota and food allergy. Clin Rev Allergy Immunol. 2019;57:83-97.
135. Sestito S, D'auria E, Baldassarre ME, et al. The role of prebiotics and probiotics in prevention of allergic diseases in infants. Front Pediatr. 2020;8:583946.
136. Yousefi B, Eslami M, Ghasemian A, et al. Probiotics importance and their immunomodulatory properties. J Cell Physiol. 2019;234:8008-8018.
137. Jones SE, Paynich ML, Kearns DB, et al. Protection from intestinal inflammation by bacterial exopolysaccharides. J Immunol. 2014;192:4813-4820.
138. Guo SS, Gillingham T, Guo YM, et al. Secretions of Bifidobacterium infantis and Lactobacillus acidophilus protect intestinal epithelial barrier function. J Pediatr Gastroenterol Nutr. 2017;64:404-412.
139. Cox MJ, Huang YJ, Fujimura KE, et al. Lactobacillus casei abundance is associated with profound shifts in the infant gut microbiome. PLoS ONE. 2010;5:e8745.
140. Canani RB, Sangwan N, Stefka AT, et al. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants. ISME J. 2016;10:742-750.
141. Fu L, Fu S, Wang C. Yogurt-sourced probiotic bacteria alleviate shrimp tropomyosin-induced allergic mucosal disorders, potentially through microbiota and metabolism modifications. Allergol Int. 2019;68:506-514.
142. Kepert I, Fonseca J, Muller C, et al. D-tryptophan from probiotic bacteria influences the gut microbiome and allergic airway disease. J Allergy Clin Immunol. 2017;139:1525-1535.
143. Kim S, Kim JH, Park BO, et al. Perspectives on the therapeutic potential of short-chain fatty acid receptors. Bmb Rep. 2014;47:173-178.
144. Overby HB, Ferguson JF. Gut microbiota-derived short-chain fatty acids facilitate microbiota: host cross talk and modulate obesity and hypertension. Curr Hypertens Rep. 2021;23:8.
145. Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. Proc Nutr Soc. 2003;62:67-72.
146. Goverse G, Molenaar R, Macia L, et al. Diet-derived short chain fatty acids stimulate intestinal epithelial cells to induce mucosal tolerogenic dendritic cells. J Immunol. 2017;198:2172-2181.
147. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451-455.
148. Kim JH, Jeun EJ, Hong CP, et al. Extracellular vesicle-derived protein from Bifidobacterium longum alleviates food allergy through mast cell suppression. J Allergy Clin Immunol. 2016;137:507-516.
149. Lee SY, Lee SH, Jhun J, et al. A combination with probiotic complex, zinc, and coenzyme Q10 attenuates autoimmune arthritis by regulation of Th17/Treg balance. J Med Food. 2018;21:39-46.
150. Huang CH, Lin YC, Jan TR. Lactobacillus reuteri induces intestinal immune tolerance against food allergy in mice. J Funct Food. 2017;31:44-51.
151. Hyung KE, Moon BS, Kim B, et al. Lactobacillus plantarum isolated from kimchi suppress food allergy by modulating cytokine production and mast cells activation. J Funct Food. 2017;29:60-68.
152. Choudhary P, Kathuria D, Suri S, et al. Fecal probiotics-its functions and influence on the ageing process: a comprehensive review. Biocatal Agric Biotechnol. 2023;52:102389.
153. Reddy MS, Reddy DRK. Anti-aging: review and experimental clinical study of bio available calcium. Int J Pharm Sci Nanotech. 2011;4(1):1436-1444.
154. Amara AA, Shibl A. Role of probiotics in health improvement, infection control and disease treatment and management. Saudi Pharm J. 2015;23(2):107-114.
155. Bektas A, Schurman SH, Sen R, Ferrucci L. Aging, inflammation and the environment. Exp Gerontol. 2018;105:10-18.
156. Butel MJ. Probiotics, gut microbiota and health. Med Mal Infect. 2014;44(1):1-8.
157. Ferrucci L, Corsi A, Lauretani F, et al. The origins of age-related proinflammatory state. Blood. 2005;105(6):2294-2299.
158. Finamore A, Roselli M, Imbinto A, Sepe Almada P, Mengheri E. Supplementation with Bifidobacterium longum Bar33 and Lactobacillus helveticus Bar13 mixture improves immunity in elderly humans (over 75 years) and aged mice. Nutrition. 2019;63-64:184-192.
159. Foster JA, Rinaman L, Cryan JF. Stress & the gut-brain axis: regulation by the microbiome. Neurobiol Stress. 2017;7:124-136.
160. Hachem JP, Crumrine D, Fluhr J, Brown BE, Feingold KR, Elias PM. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. J Invest Dermatol. 2003;121(2):345-353.
161. Reddy MS. Selected Multiphase Treatment for Coronavirus Respiratory Infections. US Patent 11,077,052 B1. August 3, 2021.
162. Reddy, MS. Mechanism of Thrombosis During COVID-19 Infection Due to SARS-CoV-2 Virus and its Variants, and a Clinically Proven Strategy to Combat with Probiotics and their Immunomodulins. Medical Research Archives. 2022;10(9);1-21. https://doi.org/10.18103/mra.v10i9.3075.
163. Reddy MS. Scientific and medical research on Dr. M.S. Reddy’s multiple mixed strain probiotic therapy and its influence on assisting to cure or prevent the nosocomial infections, synergistically enhancing the conventional cancer therapies, as an adjuvant, and its possible potential to prevent or cure COVID-19 novel Coronavirus infection by balancing the intestinal microbiota and microbiome through modulation of the human immune system. Int J Pharm Sci Nanotech. 2020;13(3):4876-4906.
164. Reddy MS. Prevention of Viral Transmission by Naked Genetic Material. US Patent 11,643,641 B2. May 9, 2023.
165. Reddy MS, Reddy DRK, Prasad NAV. Herbal and Pharmaceutical Drugs Enhanced with Probiotics. US Patent 6,080,401. June 27, 2000.
166. Reddy MS, Reddy DRK. Development of multiple mixed strain probiotics for “probiotic therapy” under clinical conditions, to prevent or cure the deadly hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus aureus (MRSA). Int J Pharm Sci Nanotech. 2016;9(3):3256-3281.
167. Reddy MS. Probiotics: genesis, current definition, and proven therapeutic properties. JAAPI. 2021;1(2):18-26.
168. Reddy MS. Proven novel method to curtail COVID-19 pandemic, long COVID, any further viral pandemics, including influenza due to RNA/DNA viruses, through inactivation of their naked RNA/DNA, and hospital acquired (nosocomial) infections. Arch Neurol & Neurosci. 2023;16(1):1-20.
169. Reddy MS. Dr. M.S. Reddy’s multiple mixed strain probiotics adjuvant cancer therapy, to complement immune check point therapy and other traditional cancer therapies, with least autoimmune side effects through eco-balance of human microbiome. Int J Pharm Sci Nanotech. 2018;11(6):4295-4317.
170. Reddy MS. Immunomodulatory effect of “Dr. M.S. Reddy’s multiple mixed strain probiotic therapy “, to cure or prevent hospital acquired (nosocomial) infections due to Clostridium difficile (C. diff), other pathogenic bacteria and autoimmune diseases. Int J Pharm Sci Nanotech. 2018;11(1):3937-3949.
171. Reddy MS, Reddy DRK. Isolation and the determination of the major principle or causative agent behind the 2016 published breakthrough discovery of Dr. M. S. Reddy’s “multiple mixed strain probiotic therapy “, in successfully treating the lethal hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus aureus (MRSA). Int J Pharm Sci Nanotech. 2016;9(6):3556-3566.
172. Reddy MS, Reddy DRK. Therapeutic probiotics for cancer reduction. AAPI Journal. 2015;May/June:55-56.
173. Reddy MS, Reddy DRK. Probiotics, biotechnology, and Ayurvedic herbs - complementary and alternative medicine. AAPI Journal. 2004;May/June:32-33.
174. Reddy MS. Mechanism of cytokine storm in COVID-19: how can probiotics combat it? JAAPI. 2021;1(3):27-35.
175. Reddy MS. The Role of Prokaryotic (Probiotic) Produced Megamicro RNAs (memiRNAs) to Prevent or Cure Viral and Nosocomial Infections, Certain Cancers, in Conjunction with Probiotic Induced Eukaryotic Micro RNAs (miRNAs). Med Res Arch. 2024;12(12):1-21. doi:10.18103/mra.v12i12.6179